Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature

Transplantation Proceedings

Volumn 48, Issue 9, 2016, Pages 3137-3141

  Jose, A ^a,b   Yiannoullou, P ^a   Bhutani, S ^a   Denley, H ^a   Morton, M ^a   Picton, M ^a   Summers, A ^a   van Dellen, D ^a,b   Augustine, T ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; HEMOGLOBIN; IPILIMUMAB; METHYLPREDNISOLONE; OMEPRAZOLE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE KIDNEY TUBULE NECROSIS; ACUTE PYELONEPHRITIS; ADULT; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CERVICAL LYMPHADENOPATHY; CHOROID MELANOMA; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENUM ULCER; ECHOGRAPHY; EYE MELANOMA; GENERAL CONDITION DETERIORATION; GLOMERULONEPHRITIS; GRAFT RECIPIENT; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; LAPAROSCOPIC SURGERY; LARGE CELL LYMPHOMA; LIVING DONOR; MALE; METASTATIC OCULAR MELANOMA; MULTIPLE CYCLE TREATMENT; NEPHROSTOMY; OPTICAL COHERENCE TOMOGRAPHY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RETINA DETACHMENT; SPLENOMEGALY; VIREMIA; VISUAL DISORDER; ALLOTRANSPLANTATION; CHEMICALLY INDUCED; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MELANOMA; MIDDLE AGED; UVEAL NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MELANOMA; MIDDLE AGED; RENAL INSUFFICIENCY; TRANSPLANTATION, HOMOLOGOUS; UVEAL NEOPLASMS;

EID: 85006508406     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2016.07.019     Document Type: Article

References (19)

1. [1] London, N.J., Farmery, S.M., Lodge, J.P., et al. Risk of neoplasia in renal transplant patients. Lancet 346 (1995), 403–406.
2. [2] Grulich, A.E., van Leeuwen, M.T., Falster, M.O., Vajdic, C.M., Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370 (2007), 59–67.
3. [3] Zwald, F.O., Brown, M., Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65 (2011), 263–279.
4. [4] Kasiske, B.L., Snyder, J.J., Gilbertson, D.T., Wang, C., Cancer after kidney transplantation in the United States. Am J Transplant 4 (2004), 905–913.
5. [5] Matin, R.N., Mesher, D., Proby, C.M., et al. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant 8 (2008), 1891–1900.
6. [6] Walkington, L.A., Lorigan, P., Danson, S.J., Advances in the treatment of late stage melanoma. BMJ, 346, 2013, 1265.
7. [7] McCoy, K.D., Le Gros, G., The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 77 (1999), 1–10.
8. [8] Leach, D.R., Krummel, M.F., Allison, J.P., Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996), 1734–1736.
9. [9] Lin, H., Rathmell, J.C., Gray, G.S., et al. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med 188 (1998), 199–204.
10. [10] Perez, V.L., Van Parijs, L., Biuckians, A., et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6 (1997), 411–417.
11. [11] Tivol, E.A., Borriello, F., Schweitzer, A.N., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995), 541–547.
12. [12] Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
13. [13] Robert, C., Thomas, L., Bondarenko, I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
14. [14] Wolchok, J.D., Neyns, B., Linette, G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11 (2010), 155–164.
15. [15] Zhang, T., Fresnay, S., Welty, E., et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 11 (2011), 1599–1609.
16. [16] Wu, Q., Jinde, K., Endoh, M., Sakai, H., Clinical significance of costimulatory molecules CD80/CD86 expression in IgA nephropathy. Kidney Int 65 (2004), 888–896.
17. [17] Okano, K., Nitta, K., Horita, S., et al. Effect of soluble form CTLA-4 on spontaneous IgA nephropathy in ddY mice [abstract]. Nephrology, 6(Suppl 1), 2001, A3.
18. [18] Lipson, E.J., Bodell, M.A., Kraus, E.S., Sharfman, W.H., Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 32 (2014), e69–e71.
19. [19] Spain, L., Higgins, R., Gopalakrishnan, K., et al. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol 27 (2016), 1135–1137.